AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...
A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Hosted on MSN2d
Astra Invests $3.5 Billion in US as Cancer Sales RiseTop-selling cancer medicine Tagrisso was a big driver with sales up 3.5% higher than expected, while revenue from newcomer ...
AZ later said that it believes Chinese authorities are looking into whether the company’s employees had illegally imported ...
The company previously said it believes Chinese authorities are probing allegations that employees illegally imported breast-cancer drug Enhertu and liver-cancer treatment Imjudo from Hong Kong, and ...
ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback